Thank you for wrapping up 2023 with us. I know many of you have been keeping a keen eye on the market to evaluate what your next steps should be in the new year. To support that, this month I wanted to provide some data points from the GastroPlus® User Community.In 2023, three specific modules were in demand, GastroPlus was consistently cited in a range of publications, and collaborations continued to expand the applicability and reliability of GastroPlus predictions.
- Top 3 modules licensed: DDI, Metabolism & Transporter, and ADR-Ocular
- Grants and Pharma Collaborations – 6 (VBE, Locally-Acting Drugs, Long-Acting Injectables, GI tract)
- Publications citing the use of GastroPlus – 80
- GastroPlus resources added to the Resource Center – 108
Your industry colleagues increased their skills in GastroPlus this year, attending intensive workshops designed to help them get more out of our platform.
- GastroPlus workshop attendees – 640
- PBPK/PBBM courses offered – 15
- PBPK/PBBM consulting projects delivered – 125
On campuses worldwide, students and professors continued to leverage GastroPlus in their projects and research.
- University+ enrollees in 2023 – 680
- University campuses using the University+ program – 404
- University+ used in 58 different countries
As you plan for 2024 and beyond, we are here when you are ready to explore any of our PBPK/PBBM products and services. Please don’t hesitate to reach out if you have questions or need support.
By Arlene Padron